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Iron and infection. Intravenous iron therapy maintains iron There are two major categories of host defense defects
stores and decreases erythropoietin demand in patients under- in chronically uremic patients: those directly caused by
going regular dialysis therapy. Microbiology studies show a the uremic state and those caused by therapeutic inter-close relationship between the availability of iron and bacterial
ventions. Iron supplementation and metabolism play avirulence. Iron is also an essential requirement of bacteria
crucial role in the host defense mechanisms, oxygenfor multiplication in the host. Therefore, clinical conditions
associated with iron excess in the host may increase the risk transport, deoxyribonucleotide synthesis, and redox re-
for infection. Parenteral iron has already been shown in human actions. Granulocytes, macrophages, T and B lympho-
and animal studies to be harmful when administered during cytes and natural killer cells appear to differ from oneinfection. There is now convincing evidence that hydroxyl radi-
another in the amount of iron they take up and storecals, produced either by the Fenton reaction or by the iron-
and in the way in which they synthesize and use iron-catalyzed Haber-Weiss reaction, are species responsible for
the damaging effects of iron. The unavailability of iron limits binding and storage proteins [8]. This indicates that an
microbial growth but also impairs host resistance. In end-stage individual modulation of the immune system by iron
renal disease, patients’ overtreatment with iron enhances the
exists, and suggests a differentiated immune responsepre-existing risk for infectious complications caused by dialysis
with respect to iron therapy.procedure per se, malnutrition, increased intracellular calcium,
as well as low and high molecular weight uremic toxins. Intrave-
nous iron therapy may not only adversely affect phagocytes in
TRANSPORT AND STORAGE OF IRONend-stage renal disease patients, but also T and B lymphocytes.
Mammalian proteins containing iron are hemopro-
teins, iron-sulfur containing proteins, as well as iron-
Almost 90% of the patients with renal anemia will res- binding and storage proteins [9]. At physiological pH,
pond to recombinant human erythropoietin (rHuEPO) plasma iron in its ferric state [Fe(III)] is complexed to
with an increase in hemoglobin, although in a minority transferrin, each transferrin molecule having two iron-
(5% to 10%) of the patients, there is a reduction or lack binding sites [10]. To acquire new iron molecules, cells
of therapeutic efficacy [1]. A major cause for hypore- use the transferrin receptor, a homodimeric transmem-
sponsiveness or resistance to rHuEPO is iron deficiency, brane protein [11]. These receptors represent the admis-
either absolute or functional [2]. To improve the efficacy sion sites of iron into cells, and their expression limits
of rHuEPO therapy, iron deficiency in end-stage renal its access, as long as the iron-binding capacity of trans-
disease patients can be combated by either oral or intra- ferrin is not exceeded. In iron overload, mechanisms of
venous iron supplementation. Oral iron might fail to non-transferrin–bound iron come into play [12].
meet the increased demand of iron supply during The levels of transferrin receptor expression reflect
rHuEPO therapy because iron resorption is poor in he- the needs of the cell for iron uptake, which is influenced
modialysis as well as in peritoneal dialysis patients [3, 4]. by the rate of cell division, as well as by special metabolic
Intravenous iron therapy in patients undergoing regular needs such as the production of myoglobin and hemoglo-
hemodialysis treatment maintains iron stores and de- bin. Transferrin receptors are continuously internalized,
creases the required rHuEPO dose necessary to keep and iron dissociates from transferrin at low pH. Iron is
the target hemoglobin levels constant [5–7]. Parenteral transported across the endosomal membrane to intracel-
iron, however, is not free from serious side-effects such lular pools [13].
as organ siderosis or increased risk of infection, particu- Transient storage of iron is made by ferritin molecules
larly in iron-overloaded patients. [14], considered a detoxification mechanism, because
iron in its free, non-protein–bound form catalyzes the
formation of reactive oxygen species [15]. Ferritin mayKey words: erythropoietin, dialysis, bacteria, hydroxyl radicals, uremic
toxin, malnutrition. be released from cells, and there is evidence that it can
subsequently bind to lymphocytes by specific saturable 1999 by the International Society of Nephrology
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surface receptors [16]. Cellular iron homeostasis in mam- rated iron-binding proteins [33]. All of these observa-
malian cells is maintained by coordinated regulation of tions indicate that severe iron overload or parenteral
expression of the transferrin receptor and ferritin [17]. iron therapy may increase the severity of infection. The
By controlling the level of these two proteins, the cell importance of moderate or mild iron excess in determin-
is able to determine the amount of iron acquired propor- ing the risk for infectious complications remains contro-
tional to the number of transferrin receptors and the versial [22].
degree of iron sequestration proportional to the cyto- Parenteral iron is unphysiological, and in addition to
plasmic level of ferritin [18]. the beneficial effect on rHuEPO therapy in dialysis pa-
Lactoferrin is another iron-binding protein. It is a con- tients, acute and chronic side-effects might increase the
stituent of several body secretions and polymorphonu- pre-existing susceptibility to infection of these patients,
clear leukocyte (PMNL) granules [19]. Released at sites impairing their cellular and humoral immune response.
of inflammation by degranulation of PMNL, apolactofer- Various theories of cellular toxicity resulting from excess
rin binds iron, being subsequently taken up by macro- iron deposition indicate specific cytopathologic mecha-
phages, and appears to inhibit macrophage interleukin nisms, whereby chronic iron overload causes organelle
(IL)-1 production. damage and altered cell function [34]. Excess iron depo-
Living organisms from bacteria to humans have devel- sition may cause cell death as a result of membrane lipid
oped elaborate mechanisms for the acquisition, trans- peroxidation [35], initiated and perpetuated by some
port, and storage of iron. Iron deprivation in bacterial forms of cellular iron. There is now convincing evidence
cultures is associated with an inhibition of growth [20]. that hydroxyl radicals produced either by the Fenton
On the other hand, there is a close correlation between reaction or by the iron-catalyzed Haber-Weiss reaction
the availability of iron and bacterial virulence [21]. Iron are species responsible for the damaging effects of iron
is also an essential requirement of bacteria for their con- [36].
tinued multiplication in the host. Therefore, clinical con-
ditions associated with iron excess in the host may in- Fe(III) 1 O·22 ↔ Fe(II) 1 O2 (Eq.1)crease the risk for infection [22]. Injection of inorganic
iron to rodent models of bacterial infection enhances Fe(II) 1 H2O2 ↔ OH· 1 OH2 1 Fe(III) (Eq.2)the in vivo virulence of a large number of bacteria [23].
Experimental pyelonephritis in mice is aggravated by
Net: O·22 1 H2O2 ↔ O2 1 OH· 1 OH2 (Eq.3)parenteral iron administration, as documented by in-
creased bacterial growth and the severity of pathological
The unavailability of iron limits microbial growth butlesions in the kidney [24]. Microorganisms of limited
also impairs host resistance [37], including impaired lym-pathogenicity such as Yersinia enterocolitica usually caus-
phocyte mitogenic response [38] and abnormalities ining mild enteric infection may produce severe sepsis,
granulocyte function such as impaired phagocytosis, ab-intestinal perforation, or multiple abscesses in patients
normal bactericidal activity, respiratory burst, and mye-with transfusional iron overload or hereditary hemo-
loperoxidase activity [39–41]. The optimal way of infec-chromatosis [25–27]. Iron overload also facilitates viral
tion control would be, according to Hershko [22], theinfections. For example, increased prevalence of hepati-
selective depletion of iron in compartments relevant totis B virus markers has been reported in hemochro-
microbial growth. The control of infection by selectivematosis patients. Three possible mechanisms are dis-
iron depletion has been summarized beautifully bycussed: (a) iron overload may facilitate viral replication
Hershko [22] as follows: The antibacterial effect of cyto-in hepatocytes; (b) liver cells containing virus may tend
kines is mediated by intracellular iron depletion. In re-to accumulate iron; and (c) iron overload may alter the
sponse to several cytokines such as interferon (INF)-g,host response to the virus [28].
IL-1, and tumor necrosis factor (TNF), the cell depletesMany histopathological studies have documented the
its intracellular labile, metabolically active iron pool by:deposition of iron in the liver of patients with chronic
(a) enhancement of ferritin synthesis, resulting in a shiftviral hepatitis. The amount of iron accumulated corre-
of cellular iron into the relatively inert ferritin storagelates with the degree of inflammation and damage of the
compartment [42, 43]; (b) down-regulation of transferrinliver [29].
receptor production, decreasing cellular iron uptake andLactoferrin has been shown to inhibit herpes simplex
limiting iron availability for the intracellular pathogenvirus infection in vitro [30]. Lactoferrin also inhibits HIV
[44, 45]; and (c) activation of nitric oxide synthesis andand cytomegalovirus replication [31]. Iron saturation re-
formation of iron-sulfur-nitric oxide complexes [46] inverses the bactericidal effect of lactoferrin and lysozyme
order to inactivate iron-sulfur centers of vital cellular[32]. Iron-binding proteins also appear to play a role in
enzymes.humoral immunity. Antibodies and complement do not
opsonize bacteria efficiently in the absence of unsatu- It has been shown that the antibacterial effect of cyto-
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kines may be reversed by iron therapy and potentiated gests a catalytic effect of iron on the production of oxy-
gen metabolites at some step beyond the formation ofby deferoxamine treatment [47].
Increased serum ferritin in hemodialysis patients is superoxide [51]. Inhibition by deferoxamine of the iron-
mediated generation of toxic oxygen species by PMNLassociated with increased susceptibility to bacterial infec-
tion [48]. In a report of 10 patients undergoing regular prevented oxidative damage and thus enhanced the
phagocytic function of PMNL [62].hemodialysis therapy, at least nine of these patients were
overloaded (one was not tested). All patients suffered The human granulocyte membrane reductase p 97phox,
which is part of the cytochrome b558 complex, sharesfrom bacteremia, nine with Yersinia enterocolitica and
one with Yersinia pseudotuberculosis [49]. A prospective significant sequence homology to the ferric reductase of
Saccharomyces cerevisiae membrane, which functions asstudy of Boelaert et al [50] confirmed previous retrospec-
tive investigations in showing that acquired transfusion a transferrin-independent iron-uptake mechanism. It has
been shown that p 97phox is responsible for the transfer ofiron overload in hemodialysis patients is associated with
a greater risk of bacteremia. Multiple PMNL dysfunc- single electrons from nicotinamide adenine dinucleotide
across the membrane to oxygen for the production oftions have been described in iron-overloaded patients
[51–54]. If the iron-transporting proteins are saturated superoxide used in the killing of phagocytosed bacteria
[63].with iron, even transitory, which might be the case after
high-dose i.v. iron therapy, the ability of plasma to de- We investigated the functional capacity of PMNLs from
hemodialysis patients, subdivided into three groups, ac-stroy or inhibit bacterial growth is lost. This is because
the phagocytic system is overwhelmed by rapidly grow- cording to their ferritin plasma levels and transferrin
saturation (ferritin . 100 and , 350 mg/liter, ferritin ,ing organisms when iron is freely available [55].
60 mg/liter, and ferritin . 650 mg/liter but transferrin
saturation , 20%) [64]. PMNL parameters (phagocyto-
PROFESSIONAL PHAGOCYTES
sis, intracellular killing of bacteria, oxidative metabolism,
A normal environment is the prerequisite for PMNL glucose uptake, intracellular calcium) for each group
to function adequately [56]. In patients on chronic hemo- were compared with those of healthy donors, of multi-
dialysis, the major functions of PMNL such as chemo- transfused iron-overloaded hematological patients and
taxis, adhesion, degranulation, phagocytosis, bactericidal those of patients suffering from hereditary hemochro-
activity are impaired [57, 58]. The mechanisms that might matosis. Compared with PMNLs obtained from healthy
additively contribute to PMNL dysfunction in uremia subjects, hemodialysis patients with ferritin values of
include the dialysis procedure per se [58], malnutrition, more than 100 mg/liter but less than 350 mg/liter showed
increased intracellular calcium, low and high molecular mild inhibition of phagocytosis but significant inhibition
circulating plasma factors, and iron overload [59]. of intracellular killing of bacteria. Oxidative burst of
The phagocytic capacity of PMNL is significantly de- PMNLs from this group of patients was also significantly
creased with increasing the PMNL iron concentration reduced after stimulation in vitro. These dysfunctions
[54]. The acute effects of intravenous iron in hemodialy- were not affected by absolute iron deficiency. Impair-
sis patients probably depend on the availability of unsat- ment of PMNLs was markedly aggravated in hemodialy-
urated transferrin and the pace of “free” iron clearance sis patients with ferritin levels of more than 650 mg/
from the plasma. It has been shown that polynuclear liter despite a transferrin saturation of less than 20%.
iron complexes impair the phagocytic function of PMNL. Intracellular calcium concentrations under basal condi-
Limited dilutions of polynuclear complexes reveal that tions and after stimulation were not different. These
concentrations as low as 25 mm Fe(III) significantly im- data suggest that iron is responsible for the markedly
pair phagocytosis [60, 61]. The molecular weight of these decreased intracellular killing of bacteria observed in the
complexes is similar to that of the non-transferrin–bound group of hemodialysis patients with hyperferritinemia.
plasma iron found in the serum of patients with iron In this group of patients, we observed a further 50%
overload. The toxic effects of small polynuclear non- reduction of in vitro oxidative metabolism comparable
transferrin plasma Fe(III) complexes on PMNL function with iron overloaded patients, that is, polytransfused pri-
may contribute to the development of infections in pa- mary hematological patients and patients suffering from
tients with iron overtreatment. hereditary hemochromatosis. These data also suggest
In contrast, the iron-liganding molecules transferrin impaired inactivation of invading microorganisms in iron
and deferoxamine protected the PMNL against the nox- “overtreated” uremic patients. It was concluded that
ious effect of iron at concentrations just high enough to even hemodialysis patients with functional iron defi-
sequestrate all the iron. Fe(III) increased the generation ciency (high ferritin but low serum iron and low trans-
of luminol chemiluminescence by stimulated PMNL in ferrin saturation) display a significant impairment of fun-
vitro, whereas the oxygen consumption of the cells was damental PMNL functions during i.v. iron and rHuEPO
therapy. This may result in increased risk for infectiousnot altered in the presence of Fe(III). This finding sug-
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complications. Therefore, overtreatment of hemodialysis suggesting that they are capable of storing iron in greater
amounts without toxic effects compared with T cells [74].patients with i.v. iron should be avoided [64].
Similar neutrophil dysfunctions have been reported in Erythropoietin therapy in hemodialysis patients did not
iron-overloaded patients with b-thalassemia major. The significantly influence antibody responses to hepatitis B
phagocytosis of bacteria by PMNL is diminished because immunization [75].
of a combination of serum and cellular abnormalities,
and both seem to be related to the iron overload [65].
CONCLUSIONTreatment with rHuEPO leads to a decrease of iron
There is a close relationship between the availabilityof PMNLs and an improvement of phagocytosis [54].
of iron and bacterial virulence. Iron is also an essentialSimilar results have been reported after treatment with
requirement of bacteria for multiplication in the host.deferoxamine [52].
Therefore, clinical conditions associated with iron ex-
cess in the host may increase the risk for infection, as
T LYMPHOCYTES overtreatment with iron not only adversely affects
phagocytes, particularly in end-stage renal disease pa-In uremia, the coexistence of an activation state and
tients, but also T and B lymphocytes.an impaired response capacity has been demonstrated
in T lymphocytes [66]. T lymphocytes are thought to
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